Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. Home

Combination vs monotherapy in pancreatic ductal adenocarcinoma

Given the toxicity profile and efficacy results, the combination regimen of gemcitabine and capecitabine is a new standard in adjuvant care of resected pancreatic ductal adenocarcinoma (PDAC) says J. Neoptolemos. He further digs into results, presented at ASCO 2016 Annual Meeting, of combination regimen with hypoxia-activated prodrug evofosfamide and gemcitabine in previously untreated metastatic or locally advanced unresectable PDAC.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.